As Omicron rages, FDA clears Eli Lilly/AbCellera's new antibody days after $720M supply deal
The FDA has authorized a new Covid-19 antibody from Eli Lilly and AbCellera, adding a much-needed weapon to the arsenal fighting against Omicron.
Just days ago, the two companies unveiled a $720 million deal to supply 600,000 doses of the drug, bebtelovimab, to the US government. It may now be prescribed, under emergency use authorization, to adults and teenagers 12 or older with positive SARS-CoV-2 tests who are either at high risk for progression to severe disease or unable/ineligible for alternative treatment options.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.